Evidence map›Paper›PMID 40384641›Full record

ArticleQuantitative imaging in medicine and surgery2025

3D computed tomography density of stage T1 lung cancer, which value is most stable for predicting its invasiveness?

Wensong Shi, Yuzhui Hu, Guotao Chang, Yulun Yang, He Qian, Yinsen Song, Zhengpan Wei, Liang Gao, Hang Yi, Sikai Wu and 9 more

Abstract read
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Wensong Shi *Department of Thoracic Surgery, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.
Yuzhui Hu *Department of Geratology, Ninth People's Hospital of Zhengzhou, Zhengzhou, China.
Guotao ChangDepartment of Thoracic Surgery, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.
Yulun YangDepartment of Thoracic Surgery, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.
He QianDepartment of Thoracic Surgery, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.
Yinsen SongTranslational Medicine Research Center (Key Laboratory of Organ Transplantation of Henan Province), The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.
Zhengpan WeiDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liang GaoDepartment of Radiology, Ninth People's Hospital of Zhengzhou, Zhengzhou, China.
Hang YiDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sikai WuDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kun WangDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Huandong HuoDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yousheng MaoDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yingli SunDepartment of Radiology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Ming LiDepartment of Radiology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Siyuan AiDepartment of Thoracic Surgery, Liangxiang Hospital, Beijing, China.
Liang ZhaoShukun (Beijing) Technology Co., Ltd., Beijing, China.
Xiangnan LiDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Huiyu ZhengDepartment of Thoracic Surgery, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medical research indicates that computed tomography (CT) values are vital for diagnosing and predicting the invasiveness of pulmonary nodules. This study investigates which three-dimensional (3D) CT density measurement value is most stable for predicting the invasiveness of T1 stage lung adenocarcinoma and advantageous for preoperative planning. Methods: A retrospective analysis was conducted on a total of 2,080 patients with pulmonary nodules of atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive carcinoma (MIA), and invasive adenocarcinoma (IAC) confirmed by surgery in six centers including Zhengzhou People's Hospital (between November 2017 and November 2023), Cancer Hospital Chinese Academy of Medical Sciences (between August 2023 and April 2024), The First Affiliated Hospital of Zhengzhou University (between June 2023 and December 2023), Huadong Hospital Affiliated to Fudan University (between May 2012 and September 2018), Beijing Liangxiang Hospital (between May 2017 and December 2023), and the Ninth People's Hospital of Zhengzhou (between November 2017 and January 2024). Clinical history and thin-layer chest CT were collected. Patients were classified into non-invasive (AAH, AIS, MIA; n=1,297) and invasive (IAC; n=783) groups based on pathology. Thin-layer CT images were analyzed using the Shukun artificial intelligence (AI) workstation, and subgroup analysis was performed according to the 3D maximum diameter (T1a: ≤10 mm, T1b: 10 mm < T1b ≤ 20 mm, T1c: 20 mm < T1c ≤ 30 mm). 3D CT density-related features were selected, receiver operating characteristic (ROC) curves were drawn, and the area under the curve (AUC) and 95% confidence interval (CI) were calculated. Further subgroup analysis was conducted on T1a, T1b, and T1c groups to determine the most stable CT value for predicting invasiveness. Results: The study encompassed 2,080 nodules with a gender distribution of 33.17% male and 66.83% female, averaging 56.54±11.31 years. Nodule distribution: 728 (35.00%) in right upper lobe (RUL), 117 (5.62%) in right middle lobe (RML), 393 (18.89%) in right lower lobe (RLL), 531 (25.53%) in left upper lobe (LUL), and 311 (14.95%) in left lower lobe (LLL). The non-invasive group included 1,297 nodules, and the invasive group 783. The 90th percentile of CT values emerged as the most stable indicator, with an AUC of 0.863 (95% CI: 0.864-0.879), at a threshold of -241.5 Hounsfield unit (HU). Subgroup analysis confirmed the 90th percentile of CT values as the most stable predictor in all groups, with AUCs and 95% CIs of [0.830, 0.778-0.881], [0.843, 0.817-0.868], and [0.893, 0.850-0.936], respectively. Conclusions: The 90th percentile of CT values reliably predicts invasiveness in stage T1 lung adenocarcinoma. This finding facilitates the clinical assessment of its invasiveness, enabling a better grasp of the timing of clinical intervention and the formulation of surgical plans.

Indexed as

90th percentileArtificial intelligence (AI)invasivenesslung adenocarcinomathree-dimensional computed tomography values (3D CT values)

Identifiers

PMID40384641
PMCPMC12084735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.